Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label BI 201335 plus peginterferon alfa-2a and ribavirin in genotype 1 chronic hepatitis C patients who failed prior PegIFN/RBV
2011-000141-20Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of faldaprevir, ribavirin and peginterferon alfa-2a in hepatitis C virus infection, sponsored by Boehringer Ingelheim. Primary endpoint: Sustained Virological Response. Started Apr 2011; status: completed.
02
Drugs
faldaprevirribavirinpeginterferon alfa-2a
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-000141-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000141-20.